COVID-19 Hastalarında Akut Böbrek Hasarı

Ruan, Q, Yang K, Wang W,et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46: 846–848.

Yarijani ZM, Najafi H. Kidney injury in COVID-19 patients, drug development and their renal complications: Review study. Biomed. Pharmacother. 2021; 142: 111966.

Chan L, Chaudhary K, Saha A,et al. AKI in Hospitalized Patients with COVID-19. J. Am. Soc. Nephrol. 2020; 32: 151–160.

Ng JH, Hirsch JS, Hazzan A, et al. Northwell Nephrology COVID-19 Research Consortium. Outcomes among Patients Hospitalized With COVID-19 and Acute Kidney Injury. Am. J. Kidney Dis. 2021; 77: 204–215.

Gupta S, Coca SG, Chan L, et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19. J. Am. Soc. Nephrol. 2021; 32: 161–176.

Legrand M, Bell S, Forni L,et al. Pathophysiology of COVID-19 associated acute kidney injury. Nat. Rev. Nephrol. 2021; 17: 751–764.

Cantaluppi V, Guglielmetti G, Dellepiane S, et al. A call to action to evaluate renal functional reserve in patients with COVID-19. Am. J. Physiol. Physiol. 2020; 319: 792–795.

Hansrivijit P, Qian C, Boonpheng B, et al Incidence of acute kidney injury and its association with mortality in patients with COVID-19: A meta-analysis. J. Investig. Med. 2020; 68: 1261–1270.

Ouyang L, Gong Y, Zhu Y, et al. Association of acute kidney injury with the severity and mortality of SARS-CoV-2 infection: A meta-analysis. Am. J. Emerg. Med. 2020; 43: 149–157.

Clark A, Jit M, Warren-Gash C, et al. Global, Regional, and National Estimates of the Population at Increased Risk of Severe COVID-19 Due to Underlying Health Conditions in 2020: A Modelling Study. Lancet Glob. Health 2020; 8:e1003–e1017.

Martino F, Fanton G, Zanetti, F, et alIs Previous eGFR a Reliable Risk Factor for COVID-19 Death? Single Centre Analysis in Chronic Kidney Disease Patients in Northern Italy. BioMed 2022;2: 82–87.

Council EE., Ortiz A, Cozzolino M, et al. Chronic kidney disease is a key risk factor for severe COVID-19: A call to action by the ERA-EDTA. Nephrol. Dial. Transplant. 2020; 36: 87–94.

Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430–436.

Santoriello D, Khairallah P, Bomback AS. Postmortem kidney pathology findings in patients with COVID-19. J. Am. Soc. Nephrol. 2020; 31: 2158–2167.

Fukao Y, Nagasawa H, Nihei Y, et al. COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine. Clin. Exp. Nephrol. 2021;25: 1240–1246.

Mehta P, McAuley DF, Brown M, et al. on behalf of theHLH Across Speciality Collaboration, UK. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–1034.

Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J. Infect. 2020; 80: 607–613.

National Health Commission of the People’s Republic of China: Guidelines for Novel Coronavirus Infection Prevention and Treatment (Trial 7th Edition). Available online: https://wwwchinalawtranslatecom/en/coronavirus-treatment-plan-7

Alexander MP, Mangalaparthi KK, Madugundu AK, et al. Acute Kidney Injury in Severe COVID-19 Has Similarities to Sepsis-Associated Kidney Injury: A multi-omics study. Mayo Clin. Proc. 2021; 96: 2561–2575.

Zanza C, Romenskaya T, Manetti AC, et al. Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina 2022; 58: 144.

Astuti I. Ysrafil Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An Overview of Viral Structure and Host Response. Diabetes Metab. Syndr. Clin. Res. Rev. 2020;14:407–412. doi: 10.1016/j.dsx.2020.04.020.

Perico L, Benigni A, Remuzzi G. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. Nephron. 2020;144:213–221. doi: 10.1159/000507305.

Naicker S, Yang C-W, Hwang S-J, et al. The Novel Coronavirus 2019 Epidemic and Kidneys. Kidney Int. 2020;97:824–828. doi: 10.1016/j.kint.2020.03.001.

Su H, Yang M, Wan C, et al. Renal Histopathological Analysis of 26 Postmortem Findings of Patients with COVID-19 in China. Kidney Int. 2020;98:219–227. doi: 10.1016/j.kint.2020.04.003.

Caceres PS, Savickas G, Murray SL, et al. High SARS-CoV-2 Viral Load in Urine Sediment Correlates with Acute Kidney Injury and Poor COVID-19 Outcome. J. Am. Soc. Nephrol. 2021;32:2517–2528. doi: 10.1681/ASN.2021010059.

Mjaess G, Karam A, Aoun F, et al. COVID-19 and the Male Susceptibility: The Role of ACE2, TMPRSS2 and the Androgen Receptor. Prog. Urol. 2020;30:484–487. doi: 10.1016/j.purol.2020.05.007.

Rezq S, Huffman AM, Basnet J, et al.Cardiac and Renal SARS-CoV-2 Viral Entry Protein Regulation by Androgens and Diet: Implications for Polycystic Ovary Syndrome and COVID-19. Int. J. Mol. Sci. 2021;22:9746. doi: 10.3390/ijms22189746.

Yadav J, Goel G, Purwar S, et al. Clinical, Virological, and Pathological Profile of Patients Who Died of COVID-19: An Autopsy-Based Study From India. Cureus. 2022;14:e23538. doi: 10.7759/cureus.23538.

Legrand M, Bell S, Forni L, et al. Cantaluppi V. Pathophysiology of COVID-19-Associated Acute Kidney Injury. Nat. Rev. Nephrol. 2021;17:751–764. doi: 10.1038/s41581-021-00452-0.

Pan X, Xu D, Zhang H, et al.. Identification of a Potential Mechanism of Acute Kidney Injury during the COVID-19 Outbreak: A Study Based on Single-Cell Transcriptome Analysis. Intensive Care Med. 2020;46:1114–1116. doi: 10.1007/s00134-020-06026-1.

Ronco C, Reis T. Kidney Involvement in COVID-19 and Rationale for Extracorporeal Therapies. Nat. Rev. Nephrol. 2020;16:308–310. doi: 10.1038/s41581-020-0284-7.

Wishahi M., Kamal N.M. Multidisciplinary Basic and Clinical Research of Acute Kidney Injury with COVID-19: Pathophysiology, Mechanisms, Incidence, Management and Kidney Transplantation. World J. Nephrol. 2022;11:105–114. doi: 10.5527/wjn.v11.i3.105.

Sharma P, Uppal NN, Wanchoo R, et al. COVID-19–Associated Kidney Injury: A Case Series of Kidney Biopsy Findings. J. Am. Soc. Nephrol. 2020;31:1948–1958. doi: 10.1681/ASN.2020050699.

Kudose S, Batal I, Santoriello D, et al. Kidney Biopsy Findings in Patients with COVID-19. J. Am. Soc. Nephrol. 2020;31:1959–1968. doi: 10.1681/ASN.2020060802.

Shetty AA, Tawhari I, Safar-Boueri L, et al. COVID-19–Associated Glomerular Disease. J. Am. Soc. Nephrol. 2021;32:33–40. doi: 10.1681/ASN.2020060804.

Chávez-Valencia V, Orizaga-De-La-Cruz C, Lagunas-Rangel FA. Acute Kidney Injury in COVID-19 Patients: Pathogenesis, Clinical Characteristics, Therapy, and Mortality. Diseases. 2022;10:53. doi: 10.3390/diseases10030053.

Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032.

Pei G, Zhang Z, Peng J, et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. J. Am. Soc. Nephrol. 2020;31:1157–1165. doi: 10.1681/ASN.2020030276.

Velez JCQ, Caza T, Larsen C.P. COVAN Is the New HIVAN: The Re-Emergence of Collapsing Glomerulopathy with COVID-19. Nat. Rev. Nephrol. 2020;16:565–567. doi: 10.1038/s41581-020-0332-3.

Lagunas-Rangel FA, Chávez-Valencia V. High IL-6/IFN-γ Ratio Could Be Associated with Severe Disease in COVID-19 Patients. J. Med. Virol. 2020;92:1789–1790. doi: 10.1002/jmv.25900.

Ahmadian E, Hosseiniyan Khatibi SM, Razi Soofiyani S., et al. COVID-19 and Kidney Injury: Pathophysiology and Molecular Mechanisms. Rev. Med. Virol. 2021;31:e2176. doi: 10.1002/rmv.2176.

Joannidis M, Forni LG, Klein SJ, et al. Lung–Kidney Interactions in Critically Ill Patients: Consensus Report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup. Intensive Care Med. 2020;46:654–672. doi: 10.1007/s00134-019-05869-7.

Welch HK, Kellum JA, Kane-Gill SL. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2018;38:785–793. doi: 10.1002/phar.2152.

Legrand M, Bokoch MP. The Yin and Yang of the Renin–Angiotensin–Aldosterone System in Acute Kidney Injury. Am. J. Respir. Crit. Care Med. 2021;203:1053–1055. doi: 10.1164/rccm.202012-4419ED.

Dudoignon E, Moreno N, Deniau B, et al. Activation of the Renin-Angiotensin-Aldosterone System Is Associated with Acute Kidney Injury in COVID-19. Anaesth. Crit. Care Pain Med. 2020;39:453–455. doi: 10.1016/j.accpm.2020.06.006.

Schmidt M., Hajage D., Lebreton G., Monsel A., Voiriot G., Levy D., Baron E., Beurton A., Chommeloux J., Meng P., et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome Associated with COVID-19: A Retrospective Cohort Study. Lancet Respir. Med. 2020;8:1121–1131. doi: 10.1016/S2213-2600(20)30328-3.

Koyner J.L., Murray P.T. Mechanical Ventilation and the Kidney. Blood Purif. 2010;29:52–68. doi: 10.1159/000259585.

Sullivan MK, Lees JS, Drake TM, et al.. Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrol Dial Transplant 2022; 37:271–284. Largest cohort study to date describing kidney outcomes in patients hospitalised with COVID-19; 31.5% of inpatients had biochemical AKI.

Matsumoto K, Prowle JR. COVID-19-associated AKI. Curr Opin Crit Care. 2022;28(6):630-637. doi:10.1097/mcc.0000000000000988

Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 [COVID-19]. Intensive Care Med 2020; 46:854–887.

Lumlertgul N, Pirondini L, Cooney E, et al. Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study. Ann Intensive Care 2021; 11:123.

Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative [ADQI] Workgroup. Nat Rev Nephrol 2020; 16:747–764. Multinational expert consensus statement providing recommendations for diagnosis, prevention and management of COVID-19 associated AKI.

Wu B, Luo M, Wu F, et al.. Acute kidney injury associated with remdesivir: a comprehensive pharmacovigilance analysis of COVID-19 reports in FAERS. Front Pharmacol 2022; 13:692828.

Adamsick ML, Gandhi RG, Bidell MR, et al.. Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol. 2020; 31:1384–1386.

RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397:605–612.

RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2020; 396:1345–1352.

Horby P, Mafham M, Linsell L, et al.. RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020; 383:2030–2040.

Horby P, Lim WS, Emberson JR, et al.. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384:693–704.

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 [RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397:1637–1645.

Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: Consensus report of the 25th Acute Disease Quality Initiative (ADQI)Workgroup. Nat. Rev. Nephrol. 2020;16: 747–764.

Memoli B. Cytokine production in haemodialysis. Blood Purif. 1999; 17: 149–158.

Villa G, Zaragoza JJ, Sharma A, et al. Cytokine removal with high cut-off membrane: Review of literature. Blood Purif. 2014; 38: 167–173.

Ronco C, Reis T, De Rosa S. Coronavirus epidemic and extracorporeal therapies in intensive care: Si vis pacem para bellum.

Blood Purif. 2020; 49: 255–258.

Ronco C, Bagshaw SM, BellomoR, et al. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation. Blood Purif. 2021; 50: 17–27.

Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat. Rev. Nephrol. 2020;16:308–310.

Peng Z-Y, Bishop JV, Wen X-Y et al. Modulation of chemokine gradients by apheresis redirects leukocyte trafficking to different compartments during sepsis,

studies in a rat model. Crit. Care 2014;18,: R141.

Soleimani A, Taba SM, Taheri SH, et al. The effect of hemoperfusion on the outcome, clinical and laboratory findings of patients with severe COVID-19: A retrospective study. New Microbes New Infect. 2021; 44: 100937.

Akbar KSATA, Soleimanpourc GH, Mahmoodpoora A. Hemoperfusion as a potential treatment for critically ill COVID-19 patients with cytokine storm. Blood Purif. 2021; 50: 407–409.

Koc S, Uysal H. Literature Review of Hemadsorption Therapy in Severe COVID-19 Cases: A Narrative Review. Clin. Lab.2022, 68.

Song M, Winchester J, Albright RL,et al. Cytokine removal with a novel adsorbent

polymer. Blood Purif. 2004; 22: 428–434.

Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med. Exp. 2018; 6: 12.

Gruda MC, Ruggeberg KG, O’Sullivan P, et al. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads. PLoS ONE 2018; 13: e0191676.

Hawchar F, László I, Öveges N, et al. Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study. J. Crit. Care. 2019; 49: 172–178.

FDA Has Authorized the Emergency Use of CytoSorb 300 mL Device: CytoSorb 300 mL Device is Manufactured under and ISO 13485 and CE Mark Approved 2020. Available online: https://www.fda.gov/media/136866/download (accessed on

10 April 2020).

Song T, Hayanga J, Durham L, et al. CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter, Retrospective

Registry. Front. Med. 2021; 8: 773461.

Alharthy A, Faqihi F, Memish ZA, et al. Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus

acute kidney injury: A case-series. Artif. Organs 2020; 45: E101–E112.

Stockmann H, Thelen P, Stroben F, et al. CytoSorb Rescue for COVID-19 Patients With Vasoplegic. Shock and Multiple Organ Failure A Prospective, Open-Label,

Randomized Controlled Pilot Study. Crit. Care Med. 2022; 50: 964–976.

oXiris Emergency Use Authorization for the United States by FDA under EUA200164. Available online: https://www.fda.gov/media/137266/download (accessed on 23 April 2020).

Broman ME, Hansson F, Vincent J-L,et al. Endotoxin and Cytokine Reducing Properties of the oXiris Membrane in Patients with Septic Shock: A Randomized Crossover Double-Blind Study. PLoS ONE. 2019; 14: e0220444.

Schwindenhammer V, Girardot T, Chaulier K, et al. oXiris® Use in Septic Shock: Experience of Two French Centres. Blood Purif. 2019;47: 29–35.

Turani F, Barchetta R, Falco M, et al. Continuous Renal Replacement Therapy with the Adsorbing Filter oXiris in Septic Patients: A Case Series. Blood Purif. 2019; 47: 54–58.

Zhou F, Peng Z, Murugan R, et al. Blood purification and mortality in sepsis: A meta-analysis of randomized trials. Crit. Care Med. 2013; 41: 2209.

Mitrev ZK, Ugurov PA. Clinical Efficacy and Safety of Extracorporeal Blood Purification to Control Hyperinflammation and Hypercoagulabilityin COVID-19 Patients. NCT04478539. Available online: https://clinicaltrials.gov/ct2/show/NCT04478539 (accessed on 12 May 2021).

Vega O. A Randomized, Controlled Trial to Evaluate Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) in Comparison with a Semi Selective Semipermeable Membrane (Standard AN-69) in COVID-19 Associated Acute Kidney Injury: oXAKI-COV Study. Available online: https://clinicaltrials.gov/ct2/show/NCT04597034 (accessed on 12 May 2021).

Mehta Y, Mehta C, Nanda S, et al. Use of CytoSorb therapy to treat critically ill coronavirus disease 2019 patients: A case series. J. Med. Case Rep. 2021;15: 476.

Peng JY, Li L, Zhao X, et al. Hemoperfusion with CytoSorb® in Critically Ill COVID-19 Patients. Blood Purif. 2022;51: 410–416.

Nassiri AA, Hakemi MS, Miri MM, et al. Blood purification with CytoSorb in critically

ill COVID-19 patients: A case series of 26 patients. Artif. Organs. 2021;45:1338–1347.

Zhang H, Zhu G, Yan L, et al. The absorbing filter Oxiris in severe coronavirus disease 2019 patients: A case series. Artif. Organs. 2020;44:1296–1302.

Hodgins S, Abdullin M, Tidswell MA, et al. Extracorporeal Cytokine Reduction Using Oxiris Blood Purification in COVID-19. J. Am. Soc. Nephrol. 2020;31:289.

Xu X, Jia C, Luo S, et al. Effect of HA330 resin-directed hemoadsorption on a porcine acute respiratory distress syndrome model. Ann Intensive Care. Ann. Intensive Care 2017;7:84.

Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir. Res. 2019;6: e000420.

Surasit K, Srisawat N. The Efficacy of Early Additional Hemoperfusion Therapy for Severe COVID-19 Patients: A Prospective Cohort Study. Blood Purif. 2021;39:4185-4191,

Rawson TM, Wilson, RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin. Microbiol. Infect. 2021;27: 9–11.

Musuuza JS. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLoS ONE. 2021; 16: e0251170.

Alqahtani A, Alamer E, Mir M, et al. Bacterial Coinfections Increase Mortality of Severely Ill COVID-19 Patients in Saudi Arabia. Int. J. Environ. Res. Public Health 2022;19:2424.

Vincent J-L, Sakr Y, Singer M, et al. Prevalence and outcomes of infection among patients in intensive care units in 017. JAMA. 2020;323:1478–1487.

Patel A, Emerick M, Cabunoc MK, et al. Rapid Spread and Control of Multidrug-Resistant Gram-Negative Bacteria in COVID-19 Patient Care Units. Emerg. Infect. Dis.

2021;27:1234–1237.

De Rosa S, Cutuli SL, Ferrer R, et al. on behalf of the COVID-19 EUPHAS2 Collaborative Group. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: Case series from EUPHAS2 registry.

Artif. Organs. 2020;45: E187–E194.

Kaplan, A.A. Therapeutic plasma exchange: A technical and operational review. J. Clin. Apher. 2013;28:3–10.

Keith P, Day M, Perkins L, et al. A novel treatment approach to the novel coronavirus: An argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit. Care. 2020;24:128.

Zhang L, Zhai H, Ma S, et al. Efficacy of therapeutic plasma exchange in severe COVID-19 patients. Br. J. Haematol. 2020;190:e181–e183.

Patel P, Nandwani V, Vanchiere J, et al. Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A—An associated respiratory failure and hemodynamic shock. Pediatr. Crit. Care Med. 2011;12:e87–e89.

Knaup H, Stahl K, Schmidt BM, et al. Early therapeutic plasma exchange in septic shock: A prospective open-label non-randomized pilot study focusing on safety,

hemodynamics, vascular barrier function, and biologic markers. Crit. Care. 2018;22: 285.

Keith PD, Wells AH, Hodges J, et al. The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: A single-center experience. Crit. Care. 2020;24:518.

Faqihi F, Alharthy A, Alodat M, et al. Therapeutic plasma exchange in adult

critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study. J. Crit. Care. 2020; 60:328.

Daoud AM, Soliman KM, Ali, HK. Potential limitations of plasmapheresis in treatment of COVID-19 patients: How to overcome them? Ther. Apher. Dial. 2020;25:350.

Stahl K, Bode C, David S. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19. Crit. Care. 2020; 24:363.

Honore PM, Mugisha A, Kugener L, et al. Therapeutic plasma exchange as routine

therapy in septic shock and as an experimental therapy for COVID-19: We are not sure. Crit. Care. 2020;24:226.

Faqihi F, Alharthy A, Abdulaziz S, et al. Therapeutic plasma exchange in patients with life-threatening COVID-19: A randomised controlled clinical

trial. Int. J. Antimicrob. Agents. 2021;57:106334.

Napoli M, Provenzano M, Hu L, et al. Acute Kidney Injury and Blood Purification Techniques in Severe COVID-19 Patients. J. Clin. Med. 2022;11(21):6286.

Patidar GK, Land KJ, Vrielink H, et al. Understanding the role of therapeutic plasma exchange in COVID-19: Preliminary guidance and practices. Vox

Sang. 2021;116:798–807.

Cegolon L, Einollahi B, Panahi Y, et al. On Therapeutic Plasma Exchange Against Severe COVID-19- Associated Pneumonia: An Observational Clinical Study. Front. Nutr. 2022; 9: 809823.

Reis T, Anwar S, Neves FDADR, et al.. Disruptive technologies for hemodialysis: Medium and high cutoff membranes. Is the future now? J. Bras. Nefrol. 2021;43:410–416.

Zickler D, Schindler R, Willy K, et al. Medium cut-off (MCO) membranes reduce inflammation in chronic dialysis patients-a randomized controlled clinical trial. PLoS ONE. 2017; 12: e0169024.

Hodzic S, Golic D, Smajic J, et al.Complications Related to Insertion and Use of Central Venous Catheters (CVC). Med. Arch. 2014;68:300–303.

Gahlot R, Nigam C, Kumar V, et al. Catheter-related bloodstream infections. Int. J. Crit. Illn. Inj. Sci. 2014;4:162–167.

Darban M, Yarmohamadi M, Mohammadkhani MM, et al. Outcome and Complications of Hemoperfusion in Patients with COVID-19 in Intensive Care Unit: A Cross-Sectional Study. Cardiovasc. Hematol. Agents Med. Chem. 2022, Epub ahead of print.

Henriksson MM, Newman E, Witt V, et al. Adverse events in apheresis: An update of the WAA registry data. Transfus. Apher. Sci. 2016;54: 2.

Alenezi FK, Almeshari MA, Mahida R, et al. Incidence and risk factors of acute kidney injury in COVID-19 patients with and without acute respiratory distress syndrome (ARDS) during the first wave of COVID-19: A systematic review and Meta-Analysis. Ren. Fail. 2021;43:1621–1633.